United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 4 minute read Pharma Industry News AstraZeneca moves deeper into cell therapy with $1bn EsoBiotec acquisition AstraZeneca’s $1 billion acquisition of EsoBiotec signals a major shift in cell therapy innovation. Find out how this deal could transform cancer treatment. byPallavi MadhirajuMarch 24, 2025